{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:08:52Z","timestamp":1787634532127,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1442,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"RJR Oncodermatology Fund"},{"name":"NIH"},{"name":"NCI"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1093\/annonc\/mdv390","type":"journal-article","created":{"date-parts":[[2015,9,20]],"date-time":"2015-09-20T00:18:32Z","timestamp":1442708312000},"page":"2496-2502","source":"Crossref","is-referenced-by-count":57,"title":["Alopecia in patients treated with molecularly targeted anticancer therapies"],"prefix":"10.1016","volume":"26","author":[{"given":"V.R.","family":"Belum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Marulanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ensslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gorcey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Busam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1093\/annonc\/mdv390_bb0010","first-page":"149","article-title":"Dermatologic toxicities of targeted anticancer therapies","volume":"8","author":"Balagula","year":"2010","journal-title":"J Support Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdv390_bb0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdv390_bb0020","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermat"},{"issue":"1","key":"10.1093\/annonc\/mdv390_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.sder.2008.12.001","article-title":"Chemotherapy-induced alopecia","volume":"28","author":"Trueb","year":"2009","journal-title":"Semin Cutan Med Surg"},{"issue":"10","key":"10.1093\/annonc\/mdv390_bb0030","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pon.3531","article-title":"Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients","volume":"23","author":"Choi","year":"2014","journal-title":"Psychooncology"},{"issue":"4","key":"10.1093\/annonc\/mdv390_bb0035","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00002820-199408000-00006","article-title":"Social and cultural dimensions of hair loss in women treated for breast cancer","volume":"17","author":"Freedman","year":"1994","journal-title":"Cancer Nurs"},{"issue":"1","key":"10.1093\/annonc\/mdv390_bb0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00002820-200601000-00006","article-title":"Postmenopausal women with breast cancer: their experiences of the chemotherapy treatment period","volume":"29","author":"Browall","year":"2006","journal-title":"Cancer Nurs"},{"key":"10.1093\/annonc\/mdv390_bb0045","unstructured":"United States Food and Drug Administration [Internet]. Silver Springs: The Organization (cited 12 July 2014). Drugs. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm (10 July 2014, date last accessed)."},{"key":"10.1093\/annonc\/mdv390_bb0050","unstructured":"US National Library of Medicine [Internet]. Bethesda: The Organization (cited 12 July 2014). Clinical Trial Registry Numbers in MEDLINE\u00ae\/PubMed\u00ae Records. http:\/\/www.nlm.nih.gov\/bsd\/policy\/clin_trials.html (21 February 2014, date last accessed)"},{"key":"10.1093\/annonc\/mdv390_bb0055","unstructured":"National Cancer Institute [Internet]. Bethesda: The Organization (cited 12 July 2014). Cancer Therapy Evaluation Program: Protocol Development. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm (20 March 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv390_bb0060","series-title":"Comprehensive Meta-analysis Version 2","author":"Borenstein","year":"2005"},{"issue":"3","key":"10.1093\/annonc\/mdv390_bb0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"9","key":"10.1093\/annonc\/mdv390_bb0070","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","article-title":"Quantitative synthesis in systematic reviews","volume":"127","author":"Lau","year":"1997","journal-title":"Ann Int Med"},{"issue":"3","key":"10.1093\/annonc\/mdv390_bb0075","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","article-title":"Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study","volume":"13","author":"Ciuleanu","year":"2012","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1093\/annonc\/mdv390_bb0080","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer","volume":"28","author":"Lam","year":"2010","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1093\/annonc\/mdv390_bb0085","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdv390_bb0090","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9829","key":"10.1093\/annonc\/mdv390_bb0095","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"9863","key":"10.1093\/annonc\/mdv390_bb0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"9863","key":"10.1093\/annonc\/mdv390_bb0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1093\/annonc\/mdv390_bb0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1093\/annonc\/mdv390_bb0115","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermat"},{"issue":"4","key":"10.1093\/annonc\/mdv390_bb0120","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdv390_bb0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1093\/annonc\/mdv390_bb0130","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","author":"Kudo","year":"2011","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdv390_bb0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","article-title":"A randomized phase II trial of maintenance therapy with sorafenib in front-line ovarian carcinoma","volume":"130","author":"Herzog","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"9940","key":"10.1093\/annonc\/mdv390_bb0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"9544","key":"10.1093\/annonc\/mdv390_bb0145","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1093\/annonc\/mdv390_bb0150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"New Engl J Med"},{"issue":"23","key":"10.1093\/annonc\/mdv390_bb0155","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1158\/1078-0432.CCR-12-1796","article-title":"A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission","volume":"18","author":"Kaye","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1093\/annonc\/mdv390_bb0160","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdv390_bb0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"New Engl J Med"},{"issue":"27","key":"10.1093\/annonc\/mdv390_bb0170","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1093\/annonc\/mdv390_bb0175","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1016\/j.ejca.2013.06.035","article-title":"Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer","volume":"49","author":"Lee","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdv390_bb0180","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/cncr.28591","article-title":"A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma","volume":"120","author":"Li","year":"2014","journal-title":"Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdv390_bb0185","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2007.13.2720","article-title":"Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2","volume":"26","author":"Lilenbaum","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdv390_bb0190","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1093\/annonc\/mdv390_bb0195","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1093\/annonc\/mdv390_bb0200","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"issue":"9","key":"10.1093\/annonc\/mdv390_bb0205","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1093\/annonc\/mdv390_bb0210","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2006.06.1853","article-title":"Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1093\/annonc\/mdv390_bb0215","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdv390_bb0220","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1523-1747.2000.00951.x","article-title":"Regular articles: conditional disruption of hedgehog signaling pathway defines its critical role in hair development and regeneration","volume":"114","author":"Wang","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1093\/annonc\/mdv390_bb0225","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/1523-1747.ep12264708","article-title":"Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages","volume":"83","author":"Nanney","year":"1984","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1093\/annonc\/mdv390_bb0230","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/1523-1747.ep12371760","article-title":"Effects of EGF on the morphology and patterns of DNA synthesis in isolated human hair follicles","volume":"102","author":"Philpott","year":"1994","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1093\/annonc\/mdv390_bb0235","first-page":"1959","article-title":"Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development","volume":"150","author":"Hansen","year":"1997","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1093\/annonc\/mdv390_bb0240","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdv390_bb0245","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.0022-202X.2005.23693.x","article-title":"Comprehensive analysis of FGF and FGFR expression in skin: FGF18 is highly expressed in hair follicles and capable of inducing anagen from telogen stage hair follicles","volume":"124","author":"Kawano","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1093\/annonc\/mdv390_bb0250","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jdermsci.2006.03.012","article-title":"PDGF isoforms induce and maintain anagen phase of murine hair follicles","volume":"43","author":"Tomita","year":"2006","journal-title":"J Dermatol Sci"},{"issue":"2","key":"10.1093\/annonc\/mdv390_bb0255","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","article-title":"Pathobiology of chemotherapy-induced hair loss","volume":"14","author":"Paus","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdv390_bb0260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1093\/annonc\/mdv390_bb0265","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2133.2009.09214.x","article-title":"Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors","volume":"161","author":"Osio","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1093\/annonc\/mdv390_bb0270","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jaad.2009.08.024","article-title":"Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib","volume":"64","author":"Hepper","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1093\/annonc\/mdv390_bb0275","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1365-2230.2010.03852.x","article-title":"Folliculitis decalvans associated with erlotinib","volume":"35","author":"Hoekzema","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"10.1093\/annonc\/mdv390_bb0280","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdv390_bb0285","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","volume":"142","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1093\/annonc\/mdv390_bb0290","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/11531920-000000000-00000","article-title":"Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors","volume":"12","author":"Cohen","year":"2011","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1093\/annonc\/mdv390_bb0295","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2010.31.9624","article-title":"Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials","volume":"29","author":"Seruga","year":"2011","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1093\/annonc\/mdv390_bb0300","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of safety results in published reports of randomized controlled trials","volume":"169","author":"Pitrou","year":"2009","journal-title":"Arch Int Med"},{"issue":"11","key":"10.1093\/annonc\/mdv390_bb0305","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/00007611-197511000-00009","article-title":"Male pattern baldness: classification and incidence","volume":"68","author":"Norwood","year":"1975","journal-title":"South Med J"},{"issue":"8","key":"10.1093\/annonc\/mdv390_bb0310","first-page":"WC01","article-title":"A hospital-based study to determine causes of diffuse hair loss in women","volume":"9","author":"Malkud","year":"2015","journal-title":"J Clin Diag Res"},{"issue":"10","key":"10.1093\/annonc\/mdv390_bb0315","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00403-011-1173-5","article-title":"Androgenetic alopecia in policemen: higher prevalence and different risk factors relative to the general population (KCIS no","volume":"303","author":"Su","year":"2011","journal-title":"23). Arch Dermatol Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419357217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419357217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/12\/2496\/16700147\/mdv390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:54:59Z","timestamp":1624521299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419357217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0923753419357217"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv390","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}